MDT-AP-3185
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 106.68
- os_event
- false
- age_years
- 40
- sex
- M
- fusion
- other ZFTA
- new_clusters
- C1
- umap1_2d
- 4.195537684
- umap2_2d
- 0.787649432
- umap1_3d
- 0.30166517
- umap2_3d
- -2.867701895
- umap3_3d
- -0.872742576
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.430
- E2F_TARGETS+0.400
- MITOTIC_SPINDLE+0.180
- SPERMATOGENESIS+0.180
- MTORC1_SIGNALING+0.170
- DNA_REPAIR+0.160
- TGF_BETA_SIGNALING+0.160
- TNFA_SIGNALING_VIA_NFKB+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.120
- P53_PATHWAY+0.110
Top 10 suppressed
- PROTEIN_SECRETION-0.330
- ALLOGRAFT_REJECTION-0.310
- INTERFERON_ALPHA_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- INTERFERON_GAMMA_RESPONSE-0.280
- COMPLEMENT-0.250
- ANDROGEN_RESPONSE-0.240
- UV_RESPONSE_DN-0.190
- ANGIOGENESIS-0.180
- IL2_STAT5_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10842373 | — | — | 0.801 |
| 2 | MDT-AP-3401 | Med | Medulloblastoma | 0.757 |
| 3 | SRR15030862 | — | — | 0.757 |
| 4 | BS_QB84TBA3 | high-grade glioma | — | 0.749 |
| 5 | R399 | — | — | 0.745 |
| 6 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.744 |
| 7 | MDT-AP-1156 | Med | Medulloblastoma | 0.742 |
| 8 | TCGA-E9-A1N8-01A-11R-A144-07 | — | E | 0.740 |
| 9 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.739 |
| 10 | SRR6013543 | — | cohortSQ1 | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |